Molecular Profile of Advanced Cutaneous Squamous Cell Carcinoma.

BACKGROUND: Patients with advanced cutaneous squamous cell carcinoma (cSCC) frequently have high tumor mutation burdens (TMBs) but cannot tolerate immunotherapy due to comorbid conditions or already immunosuppressed states. OBJECTIVE: We considered whether these patients might be good candidates for targeted therapy if unique genetic mutations are identified. METHODS: Biopsies of primary tumors or metastases of advanced cSCC from seven patients were sent for FoundationOne testing. Genomic alterations and TMBs were compiled from these samples and used to tailor therapy when possible. Patients were followed for changes in their disease burden. RESULTS: Eight biopsies taken from seven patients were sent for FoundationOne testing. Sixty-three genomic alterations were identified. Thirteen genes had mutations occur more than once, with mutations in TP53 being the most frequently identified (100% of patients). In one patient, an ERBB3 mutation was identified, and lapatinib was added to nivolumab for a six-month course of treatment, after which point the patient experienced stabilization of disease without progression for two years as of the most recent follow-up. CONCLUSION: More routine investigation of cSCC tumors with next-generation sequencing can help to identify unique mutations that respond favorably to targeted therapy in these notoriously difficult-to-treat malignancies.

Depth of Invasion of Aggressive and Nonaggressive Basal Cell Carcinoma.

Objective: Dermal invasion is characteristic of more aggressive basal cell carcinoma (BCC) tumors. However, reporting the depth of invasion of BCC is not currently a standard or recommended practice. The purpose of this study was to document the depth of invasion of BCC. Design: Original hematoxylin and eosin-stained slides of biopsied BCCs (N=500) were reviewed. The depth of invasion was measured for each case. Each case was also determined to be aggressive or nonaggressive based on the presence of additional histologic features. Setting: Biopsy specimens from a large private practice were reviewed. Measurements: Descriptive statistics were calculated for all cases. To compare the average depth of invasion of cases with aggressive features versus cases with nonaggressive features, two-tailed, independent t-tests were computed. Results: The overall median depth of invasion was 0.68mm (range: 0.10-5.49). The median depth of invasion of aggressive cases (n=68) was 1.04mm, while the median depth of invasion of nonaggressive cases (n=432) was 0.62mm. The difference between median depth of invasion of aggressive and nonaggressive cases was found to be significant (p<0.0001). This significant difference (p<0.0001) was maintained even with transection, which was present in the majority of cases (n=347; 69.4%). Conclusions: Dermal invasion depths of all subtypes of BCC have not been previously reported. The median dermal invasion of histologically aggressive BCC is greater than nonaggressive tumors. These findings might help clinicians in determining the depth of biopsy and choice of treatment.

Trauma care does not discriminate: The association of race and health insurance with mortality following traumatic injury.

BACKGROUND: Previous studies have reported that black race and lack of health insurance coverage are associated with increased mortality following traumatic injury. However, the association of race and insurance status with trauma outcomes has not been examined using contemporary, national, population-based data. METHODS: We used data from the National Inpatient Sample on 215,615 patients admitted to 1 of 836 hospitals following traumatic injury in 2010. We examined the effects of race and insurance coverage on mortality using two logistic regression models, one for patients younger than 65 years and the other for older patients. RESULTS: Unadjusted mortality was low for white (2.71%), black (2.54%), and Hispanic (2.03%) patients. We found no difference in adjusted survival for nonelderly black patients compared with white patients (adjusted odds ratio [AOR], 1.04; 95% confidence interval [CI], 0.90-1.19; p = 0.550). Elderly black patients had a 25% lower odds of mortality compared with elderly white patients (AOR, 0.75; 95% CI, 0.63-0.90; p = 0.002). After accounting for survivor bias, insurance coverage was not associated with improved survival in younger patients (AOR, 0.91; 95% CI, 0.77-1.07; p = 0.233). CONCLUSION: Black race is not associated with higher mortality following injury. Health insurance coverage is associated with lower mortality, but this may be the result of hospitals' inability to quickly obtain insurance coverage for uninsured patients who die early in their hospital stay. Increasing insurance coverage may not improve survival for patients hospitalized following injury. LEVEL OF EVIDENCE: Epidemiologic and prognostic study, level III.